Onderzoeker
Jacques De Grève
- Trefwoorden:Geneeskunde
- Disciplines:Kankerbiologie, Kankertherapie, Kankerpreventie
Affiliaties
- Medische genetica (Departement)
Lid
Vanaf1 mei 2019 → Heden - Laboratorium Moleculaire Oncologie (Onderzoeksgroep)
Lid
Vanaf1 jan 2010 → Heden - Observerende Klinische wetenschappen (Departement)
Lid
Vanaf1 okt 2023 → Heden - Observerende Klinische wetenschappen (Departement)
Lid
Vanaf27 mei 2019 → 30 sep 2019 - Observerende Klinische wetenschappen (Departement)
Lid
Vanaf8 apr 2019 → 30 sep 2023 - Observerende Klinische wetenschappen (Departement)
Lid
Vanaf1 jan 2014 → 20 okt 2022 - Medische Oncologie (Departement)
Lid
Vanaf1 jul 2012 → 30 apr 2019 - Medische Oncologie (Departement)
Lid
Vanaf1 jun 2010 → 31 dec 2011 - Inwendige Geneeskundige Specialiteiten (Departement)
Lid
Vanaf25 apr 2005 → 31 dec 2013 - Medische Beeldvorming en Fysische Wetenschappen (Departement)
Lid
Vanaf1 jan 1999 → 24 apr 2005
Projecten
1 - 5 of 5
- Interdiscliplinair Netwerk in Fundamenteel en Medisch Onderzoek op Long- en PancreaskankerVanaf1 jul 2021 → HedenFinanciering: BOF - projecten
- Interdisciplinair Netwerk voor Fundamenteel en Medische Onderzoek naar LongkankerVanaf1 jul 2016 → 30 jun 2021Financiering: Univ. - Projectmatig onderzoek
- Innovatie door Combinatie: Identificatie van een nieuwe combinatietherapie voor verbeterde behandeling van EGFRVanaf1 jan 2016 → 31 dec 2019Financiering: FWO mandaten
- BruBreast: Ontwikkeling van diagnostische en therapeutische instrumenten voor het optimale beheer van de individuele kankerpatiënt.Vanaf1 jun 2008 → 31 mei 2011Financiering: Brussels Hoofdstedelijk Gewest
- Kritische mutaties en signalen in borstkankercellen en hun stromale omgeving.Vanaf1 jan 2008 → 31 dec 2009Financiering: FWO Onderzoeksproject (incl. WEAVE projecten)
Publicaties
1 - 10 van 140
- Identification of RAD17 as a candidate cancer predisposition gene in families with histories of pancreatic and breast cancers(2024)
Auteurs: Sofie Joris, Philippe Giron, Catharina Olsen, Sara Seneca, Alexander Gheldof, Shula Staessens, Rajendra Bahadur Shahi, Sylvia De Brakeleer, Erik Teugels, Jacques De Grève, et al.
- Phase II Trial Assessing the Repeatability and Tumor Uptake of [68Ga]Ga-HER2 Single-Domain Antibody PET/CT in Patients with Breast Carcinoma(2024)
Auteurs: Odrade Gondry, Vicky Caveliers, Catarina Xavier, Marian Vanhoeij, Guy Verfaillie, Christel Fontaine, Katrien Glorieus, Jacques De Grève, Sofie Joris, Ine Luyten, et al.
Pagina's: 178-184 - Realizing the power of cancer genetics(2024)
Auteurs: Sofie Joris, Frederik J Hes, Jacques De Grève
Aantal pagina's: 108 - Overcoming drug tolerance to enhance the efficacy of EGFR tyrosine kinase inhibitors(2024)
Auteurs: Carolien Eggermont, Ilse Rooman, Jacques De Grève, Gustavo J Gutierrez, Philippe Giron
Aantal pagina's: 158 - Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study(2023)
Auteurs: Sofie Joris, H. Denys, Joelle Collignon, M. Rasschaert, Daphne t'Kint de Roodenbeke, Francois P Duhoux, J-L Canon, S. Tejpar, J Mebis, Lore Decoster, et al.
- Inhibition of PLK1 Destabilizes EGFR and Sensitizes EGFR-Mutated Lung Cancer Cells to Small Molecule Inhibitor Osimertinib(2023)
Auteurs: Carolien Eggermont, Gustavo Gutierrez Gonzalez, Jacques De Grève, Philippe Giron
- Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia(2023)
Auteurs: Robert J Kreitman, Philippe Moreau, Farhad Ravandi, Martin Hutchings, Anas Gazzah, Anne-Sophie Michallet, Zev A Wainberg, Alexander Stein, Sascha Dietrich, Maja J A de Jonge, et al.
Pagina's: 996-1006 - Second generation Spautin-1 analogues targeting EGFR-mutant non-small cell lung cancer cells(2023)
Auteurs: Mathias Elsocht, Philippe Giron, Jacques De Grève, Steven Ballet
- PRECISION(2022)
Auteurs: J Thouvenin, C Van Marcke, Lore Decoster, Gordana Raicevic, Kevin Punie, M. Vandenbulcke, R A Salgado, Els Van Valckenborgh, Bart Maes, Sofie Joris, et al.
- The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer(2022)
Auteurs: Carolien Eggermont, Philippe Giron, Maxim Noeparast, Hugo Vandenplas, Pedro Aza-Blanc, Gustavo J Gutierrez, Jacques De Grève
Gelinkte datasets
1 - 6 van 6
- Additional file 6: of Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families (Creator)
- Additional file 1: of Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families (Creator)
- Additional file 3: of Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families (Creator)
- Additional file 11: of Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families (Creator)
- Additional file 9: of Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families (Creator)
- Additional file 4: of Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families (Creator)